Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]

Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original article

Guardado en:
Detalles Bibliográficos
Autores principales: Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris III HA, Zamboni WC
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/f7e040c8333d42af9a814346b023d546
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares